

Pharmacy Medical Necessity Guidelines: Anti-emetic Medications

Effective: November 12, 2024

These pharmacy medical necessity guidelines apply to the following: Tufts Health RITogether – A Rhode Island Medicaid Plan				Fax Numbers: RXUM: 617.673.0939	
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review		RXUM	
Not Covered		Type of Review – Clinical Review $$		\checkmark	
Prior Authorization Required	\checkmark	Type of Review – Care	Managem	ent	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Syndros (dronabinol oral solution) is a cannabinoid indicated in adults for the treatment of anorexia associated with weight loss in patients with AIDS. It is also approved for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic therapies. Dronabinol is available as capsules and oral solution. Dronabinol capsules are the preferred formulation for RITogether.

Diclegis (doxylamine/pyridoxine) and Bonjesta (doxylamine/pyridoxine ER) are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Anzemet (dolasetron) tablet is a 5-HT₃ antagonist indicated for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy in adults and children 2 years of age and older.

Aprepitant capsule is a substance P/neurokinin 1 (NK₁) receptor antagonist indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy (including high-dose cisplatin), and nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy. The capsules are also approved for prevention of postoperative nausea and vomiting (PONV) in adults. Aprepitant capsule is the preferred NK1 receptor antagonist for RITogether and is covered without Prior Authorization.

Emend oral suspension (aprepitant) is indicated in combination with other antiemetic agents, in patients 6 months of age and older, for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. It is also approved for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.

Akynzeo (netupitant/palonosetron) oral capsule is a fixed combination of an NK_1 receptor antagonist and a serotonin-3 ($5HT_3$) receptor antagonist indicated in combination with dexamethasone for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Oral palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Akynzeo capsule is administered approximately one hour prior to the start of chemotherapy.

Sancuso (granisetron) transdermal is a 5-HT $_3$ receptor antagonist indicated for the prophylaxis of nausea and vomiting associated with moderately or highly emetogenic chemotherapy for up to five consecutive days.

Varubi (rolapitant) tablet is an NK₁ receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

The American Society of Clinical Oncology (ASCO) established a grading system to determine the likelihood of emesis following treatment with a chemotherapeutic regimen. Guidelines for the treatment of chemotherapy induced nausea and vomiting (CINV) are based on the emetogenicity of the treatment regimen. The 2020 ASCO antiemesis guidelines recommend the use of an NK₁ receptor antagonist in combination with a 5-HT₃ receptor antagonist, dexamethasone, and olanzapine for adult patients on antineoplastic agents with high-emetic risk. Adult patients being treated with a moderately emetogenic

chemotherapy regimen should be treated with a $5-HT_3$ receptor antagonist and dexamethasone. However, patients being treated with carboplatin area under the curve (AUC) ≥ 4 mg/mL/min should be treated with an NK₁ receptor antagonist, a $5-HT_3$ receptor antagonist, and dexamethasone. A single dose of a $5-HT_3$ receptor antagonist or a single 8-mg dose of dexamethasone prior to chemotherapy is suggested for patients being treated with regimen with low emetogenic potential. The table below lists the level of emetogenicity of intravenous antineoplastic agents in adults. Emetogenicity is based on chemotherapeutic drug and dose. For multi-drug regimens with varying levels of emetogenicity, the overall emetogenicity of the regimen is based on the drug component with the greatest emetic risk.

High (>90%) Anthracycline/cyclophosphamide Carmustine Decarbazine Mechlorethamine Cisplatin Cyclophosphamide ≥ 1500 mg/m² Mechlorethamine Moderate (30-90%) Alemtuzumab Doxorubicin* Arsenic trioxide Epirubicin* Epirubicin* Acacitidine Idarubicin* Bendamustine Idarubicin* Clofarabine Irinotecan liposomal injection Cyclophosphamide < 1500 mg/m² Oxaliplatin Clofarabine Trinocecan Cyclophosphamide < 1500 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa Daunorubicin and cytarabine Trabezetedin Low (10-30%) Afibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Binatumomab Bortezomib Mitoxantrone Berntuximab Bortezomib Neitarabine Catumaxumab Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Peretrexed Docetaxel Tagraxofusp-erzs Eribulin	Level of	Chemotherapeutic Drug and Dose		
Carmustine Mechlorethamine Cisplatin Streptozocin Cyclophosphamide ≥ 1500 mg/m ² Doxorubicin* Moderate (30-90%) Alemtuzumab Doxorubicin* Arsenic trioxide Epirubicin* Azacitidine Idarubicin* Bendamustine Ifosfamide Carbopistin ⁺ Irinotecan Clofarabine Unitotecan Cyclophosphamide < 1500 mg/m ² Nailpatin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa Iposome Trabectedin Akicabtagene ciloleucel Ixabepilone Blinatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Neatumab Catilizerel Neatumab Catumaxumab Pacilitatel and nab-pacilitaxel Catumaxumab Pagylated liposomal doxorubicin Cytapibine ≤ 1000 mg/m ² Pemetrexed Dectabine Tagraxofusp-erzs Eribulin Temsiolimus Catumaxumab Peruzumab Catumaxumab Peruzumab Docetaxel Tagraxofusp-erzs<	Emetogenicity			
Cisplatin Streptozocin Moderate (30-90%) Alemtuzumab Doxorubicin* Azacitidine Idarubicn* Bendamustine Ifosfamide Clofarabine Irinotecan Clofarabine Irinotecan Cyclophosphamide < 1500 mg/m² Oxaliplatin Cyclophosphamide < 1500 mg/m² Oxaliplatin Daunorubicin* Temozolomide Binatumomab Mitomycin Binatumomab Mitomycin Bortez	High (>90%)	Anthracycline/cyclophosphamide		
Cyclophosphamide ≥ 1500 mg/m² Moderate (30-90%) Alemtuzumab Doxorubicin* Arsenic trioxide Epirubicin* Bendamustine Idarubicin* Bendamustine Ifosfamide Carboplatin† Irinotecan Clofarabine Irinotecan Cyclophosphamide < 1500 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa Iposome Trabectedin Axicabtagene ciloleucel Ixabepilone Binatumomab Mitoxantrone Bortezomib Mitoxantrone Brentuximab Pacitatel Catumaxumab Pacitatel Copanlisib Pegylated liposomal doxorubicin Copanlisib Pegylated liposomal doxorubicin Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Tenstrone Brentuximab Pacitatel an nab-paclitaxel Catumaxumab Pacitatel an lanb-paclitaxel Cetuximab Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed		Carmustine	Mechlorethamine	
Moderate (30-90%) Alemtuzumab Doxorubicin* Arsenic trioxide Epirubicin* Azacitidine Idarubicin* Bendamustine Ifosfamide Carboplatin1 Irinotecan Clofarabine > 1000 mg/m2 Oxaliplatin Cyclophosphamide < 1500 mg/m2 Oxaliplatin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa liposome Trabectedin Aricabtagene ciloleucel Ixabepilone Beinostat Methotrexate Binatumomab Mitomycin Bortezomib Necitumumab Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel iposomal doxorubicin Cytarabine < 1000 mg/m2 Pemetrexed Decitabine Peruzumab Copanilsib Pegylated liposomal doxorubicin Cytarabine < 1000 mg/m2 Pemetrexed Decetaxel Tagraxofusp-erzs Eribulin Temsionimus		Cisplatin	Streptozocin	
Arsenic trioxide Epirublicin* Azacitidine Idarubicin* Bendamustine Ifosfamide Carboplatin† Irinotecan Clofarabine Irinotecan Cyclophosphamide < 1500 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicina* Temozolomide Daunorubicina* Temozolomide Daunorubicina* Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Blinatumomab Mitomycin Bortezomib Mitomycin Bortezomib Mitoxantrone Brentuximab Necitumumab Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Trastuzumab Docetaxel Tagraxofidus-erzs Eribulin Temsirolinus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemcitabine Obinutu		Cyclophosphamide \geq 1500 mg/m ²		
AzacitidineIdarubicin*BendamustineIfosfamideCarboplatin†IrinotecanClofarabineIrinotecanCyclophosphamide < 1500 mg/m²OxaliplatinCytarabine > 1000 mg/m²RomidepsinDaunorubicin*TemozolomideDaunorubicina*TemozolomideDaunorubicina*TrabectedinLow (10-30%)AfilberceptAxicabtagene ciloleucelIxabepiloneBelinostatMethotrexateBinatumomabMitomycinBortezomibNitoxantroneBeretuximabNecitumumabCatumaxumabPaclitatel and nab-paclitaxelCytarabine > 1000 mg/m²PemetrexedBortezomibNitoxantroneBortezomibNecitumumabCabazitaxelNecitumumabCatumaxumabPaclitatel and nab-paclitaxelCatumaxumabPegylated liposomal doxorubicinCytarabine < 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEripbulinTemsizolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemutzub ozogamicinVinflunineMinimal (<10%)AtezolizumabAvelumabPialtrexateBusulfanObinutuzumabCarifibineRituximabDaratumumabOfatumumabCoparitabineRituximabDaratumabVinolastineEmapalumabVinoristine	Moderate (30-90%)	Alemtuzumab	Doxorubicin*	
BendamustineIfosfamideCarboplatin ⁺ IrinotecanClofarabineIrinotecanCyclophosphamide < 1500 mg/m²OxaliplatinCytarabine > 1000 mg/m²RomidepsinDaunorubicin*TemozolomideDaunorubicina*TemozolomideLow (10-30%)AfilberceptAfilberceptInotuzumab ozogamicinAxicabtagene ciloleucelIxabeplioneBinatumomabMitomycinBortezomibMitomycinBortezomibNeitarabineCaffizomibNeitarabineCaffizomibNeitarabineCaffizomibNeitarabineCatumaxumabPacitatel and nab-paclitaxelCatuaxumabPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabAvelumabPralatrexateBleomycinNivolumabBusufanObinutuzumabCarbineCaturatinaCafilizomibPeralatrexateBleomycinNivolumabCotaxilabineTrastuzumabCotarbinePeralatrexateBleomycinNivolumabCotarbineCaturumabCotarbineCaturumabCotarbineCaturumabCotarbineCaturumabCotarbineCaturumabCotarbineCaturumab		Arsenic trioxide	Epirubicin*	
Carboplatin [↑] Irinotecan Clofarabine Irinotecan Clofarabine Irinotecan Cytarabine > 1000 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa liposome Trabectedin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitoxantrone Brentuximab Nectumumab Catizaxel Nectumumab Catumaxumab Paclitatel and nab-paclitaxel Copanlisib Peruzumab Copanlisib Peruzumab Copanlisib Peruzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracii Topotecan Gemtuzuab ozogamicin Vinfluine Minimal (<10%) Atezolizumab Pembrolizumab Aveclumab Prisartone Biony Penbrolizumab Penbrolizumab Avelumab Pixantrone Peruzumab Copanlisib Penbrolizumab Pacli		Azacitidine	Idarubicin*	
Clofarabine Irinotecan liposomal injection Cyclophosphamide < 1500 mg/m ² Oxaliplatin Cyclophosphamide < 1500 mg/m ² Romidepsin Daunorubicin* Temozolomide Daunorubicinand cytarabine Tribetepa liposome Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Binatumomab Mitomycin Bortezomib Mitoxantrone Berentuximab Nosetumomab pasudotox Cabazitaxel Necitumumab Catimaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Cytarabine ≤ 1000 mg/m ² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemuzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Peraterexate Bleomycin Ni		Bendamustine	Ifosfamide	
Clofarabine Irinotecan liposomal injection Cyclophosphamide < 1500 mg/m ² Oxaliplatin Cyclophosphamide < 1500 mg/m ² Romidepsin Daunorubicin* Temozolomide Daunorubicinand cytarabine Tribetepa liposome Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Binatumomab Mitomycin Bortezomib Mitoxantrone Berentuximab Nosetumomab pasudotox Cabazitaxel Necitumumab Catimaxumab Paclitatel and nab-paclitaxel Catumaxumab Paclitatel and nab-paclitaxel Cytarabine ≤ 1000 mg/m ² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemuzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Peraterexate Bleomycin Ni		Carboplatin ⁺	Irinotecan	
Cyclophosphamide < 1500 mg/m² Oxaliplatin Cytarabine > 1000 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa liposome Trabectedin Afibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methorexate Binatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Moextumomab pasudotox Cabazitaxel Necitumumab Catumaxumab Paclitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Trastuzumab emtansine Gemcitabine Praspellecleucel Fluorouracil Topotecan Gemcitabine Prastrexate Borcetaxel Pixantrone Bevacizumab Pixantrone Bevacizumab Pixantrone			Irinotecan liposomal injection	
Cytarabine > 1000 mg/m² Romidepsin Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa liposome Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitomycin Bortezornib Mitoxantrone Brentuximab Necitumumab Cafilzomib Neatarabine Catumaxumab Paclitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Docetaxel Tagraxofusp-erzs Eribulin Tensirolimus Docetaxel Tagraxofusp-erzs Eribulin Tensirolimus Gemcitabine Pratuzumab Minimal (<10%) Atezolizumab Pixantrone Bevacizumab Pixantrone Bevacizumab Avelumab Pixantrone Bevacizumab Avelumab Pixantrone Bevacizumab Avelumab Pixantrone		Cyclophosphamide < 1500 mg/m^2		
Daunorubicin* Temozolomide Daunorubicin and cytarabine Thiotepa Trabectedin Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitoxantrone Bortezomib Mitoxantrone Brentuximab Necitumumab Cabazitaxel Necitumumab Catumaxumab Pacitiatel and nab-pacitaxel Catumaxumab Pacitiatel and nab-pacitaxel Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemtrexed Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemutzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Pembrolizumab Avelumab Peixantrone Bevacizumab Avelumab Pixantrone Bevacizumab Avelumab Pixantrone Bevacizumab Atezolizumab Pembrolizumab Avelumab Avelumab Pixantrone Bevacizumab				
Daunorubicin and cytarabine Thiotepa Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Necitumumab Cabazitaxel Necitumumab Catmaxumab Paclitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pemetrexed Docetaxel Tagraxofusp-erzs Eribulin Teaspaine Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemutzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Piatrexate Busulfan Obinutuzumab Obinutuzumab Cerniplimab Obinutuzumab Cerniplimab Avelumab Pixantrone Bevacizumab Pixaltrone Revacizumab Pralatrexate Busulfan Obinutuzumab Cerniplimab Avelumab Pixantrone Busulf				
liposome Trabectedin Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Moxetumomab pasudotox Cabazitaxel Necitumumab Carfilzomib Nelarabine Catumaxumab Panitumumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Trasgenlecleucel Fluorouracil Topotecan Gemtuzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Pralatrexate Bleomycin Nivolumab Dioutuzumab Quertabine Critabine Trasturumab Gemtuzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Pralatrexate Bleomycin N				
Low (10-30%) Aflibercept Inotuzumab ozogamicin Axicabtagene ciloleucel Ixabepilone Beinostat Methotrexate Blinatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Necitumumab Cabazitaxel Necitumumab Catumaxumab Paclitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemtuzuab ozogamicin Vinflunine Minimal (<10%) Atezolizumab Pembrolizumab Avelumab Pixantrone Peavaizumab Busulfan Obinutuzumab Centurimab Centiplimab Ofatumumab 2-Chlorodeoxyadenosine Caturaturab Trastuzumab Daraturumab Daratumumab Vinblastine Daratumumab		-		
Axicabtagene ciloleucel Ixabepilone Belinostat Methotrexate Blinatumomab Mitomycin Bortezomib Mitoxantrone Brentuximab Moxetumomab pasudotox Cabazitaxel Necitumumab Catumaxumab Pacitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pengylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemcitabine Prastuzumab emtansine Gemcitabine Prastuzumab Avelumab Pixantrone Bevacizumab Pralatrexate Bleomycin Nivolumab Busulfan Ofatumumab 2-Chlorodeoxyadenosine Ramucirumab 2-Chlorodeoxyadenosine Ramucirumab 2-Chlorodeoxyadenosine Ramucirumab Darvalumab Vincristine	Low (10-30%)			
Belinostat Methotrexate Blinatumomab Mitomycin Bortezomib Mitoxantrone Bortezomib Moxetumomab pasudotox Cabazitaxel Necitumumab Carfilzomib Nelarabine Catumaxumab Paclitatel and nab-paclitaxel Cetuximab Paclitatel and nab-paclitaxel Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemcitabine Pixantrone Bevacizumab Pembrolizumab Avelumab Pixantrone Bevacizumab Pralatrexate Bleomycin Nivolumab Busulfan Obinutuzumab Cemiplimab Ofatumumab 2-Chlorodeoxyadenosine Ramucirumab Caditibine Rituximab Daratumumab Vincristine				
BlinatumomabMitomycinBortezomibMitoxantroneBrentuximabMoxetumomab pasudotoxCabazitaxelNecitumumabCarfilzomibNelarabineCatumaxumabPaclitatel and nab-paclitaxelCetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTisagenlecleucelFluorouracilTopotecanGemcitabinePrastuzumabMinimal (<10%)AtezolizumabPixantroneBevacizumabBevacizumabPralatrexateBleomycinNivolumabBusulfanOfatumumabCatifizineGratumumabCemiplimabOfatumumabZ-ChlorodeoxyadenosineRamucirumabClaribineRituximabDaratumumabVincristine				
BortezomibMitoxantroneBrentuximabMoxetumomab pasudotoxCabazitaxelNecitumumabCarfilzomibNelarabineCatumaxumabPaclitatel and nab-paclitaxelCetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemetuzab ozogamicinVinflunineMinimal (<10%)AtezolizumabPeralarrexateBeomycinAtezolizumabPralatrexateBusulfanObinutuzumabCemiplimab2-ChlorodeoxyadenosineRamucirumabCatumumabVinolumabDaratumumabVinolustineDaratumumabVincristine				
Brentuximab Moxetumomab pasudotox Cabazitaxel Necitumumab Carfilzomib Nelarabine Catumaxumab Paclitatel and nab-paclitaxel Cetuximab Panitumumab Copanlisib Pegylated liposomal doxorubicin Cytarabine ≤ 1000 mg/m² Pemetrexed Decitabine Pertuzumab Docetaxel Tagraxofusp-erzs Eribulin Temsirolimus Etoposide Tisagenlecleucel Fluorouracil Topotecan Gemcitabine Trastuzumab emtansine Gemcitabine Trastuzumab Minimal (<10%) Atezolizumab Avelumab Pixantrone Beovacizumab Pralatrexate Bleomycin Nivolumab Busulfan Obinutuzumab Cemiplimab Ofatumumab 2-Chlorodeoxyadenosine Ramucirumab Cladribine Rituximab Daratumumab Trastuzumab Decentabu Ofatumumab Compolicitate Rimucirumab Eriburi Trastuzumab Busulfan Obinutuzumab			•	
CabazitaxelNecitumumabCarfilzomibNelarabineCatumaxumabPaclitatel and nab-paclitaxelCetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCamplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabClaribineTrastuzumabDotaratumumabVincristineBaratumumabVincristine				
CarfilzomibNelarabineCatumaxumabPaclitatel and nab-paclitaxelCetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemcitabinePembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineTrastuzumabDoratumumabTrastuzumabDoratumumabVinblastineEmapalumabVincristine			•	
CatumaxumabPaclitatel and nab-paclitaxelCetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabinePembrolizumabMinimal (<10%)AtezolizumabPeratorumabPixantroneBevacizumabPralatrexateBleomycinNivolumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDotetaxuabPralatrexateBlomycinNivolumabDaratumumabTrastuzumabDaratumumabVincristineEmapalumabVincristine				
CetuximabPanitumumabCopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemcitabineTrastuzumab emtansineGemcitabinePembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineTrastuzumabDarvalumabTrastuzumabDarvalumabVinblastineDarvalumabVincristine				
CopanlisibPegylated liposomal doxorubicinCytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineTrastuzumabDaratumumabTrastuzumabDaratumumabVinblastineDaratumabVinblastineEmapalumabVincristine				
Cytarabine ≤ 1000 mg/m²PemetrexedDecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPerabelarexateBleomycinBisulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDaratumumabVinflusimabDarvalumabVincristineDaralumabVincristine				
DecitabinePertuzumabDocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine				
DocetaxelTagraxofusp-erzsEribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabVinblastineDarvalumabVincristineKinada				
EribulinTemsirolimusEtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDaratumumabVinblastineEmapalumabVincristine				
EtoposideTisagenlecleucelFluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine				
FluorouracilTopotecanGemcitabineTrastuzumab emtansineGemtuzuab ozogamicinVinflunineMinimal (<10%)AtezolizumabPembrolizumabAvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDaratumumabVinblastineEmapalumabVincristine				
Gemcitabine Gemtuzuab ozogamicinTrastuzumab emtansine OunflunineMinimal (<10%)				
Gemtuzuab ozogamicinVinflunineMinimal (<10%)			•	
Minimal (<10%)				
AvelumabPixantroneBevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine				
BevacizumabPralatrexateBleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine	Minimal (<10%)			
BleomycinNivolumabBusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		Avelumab		
BusulfanObinutuzumabCemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		Bevacizumab	Pralatrexate	
CemiplimabOfatumumab2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		Bleomycin	Nivolumab	
2-ChlorodeoxyadenosineRamucirumabCladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		Busulfan	Obinutuzumab	
CladribineRituximabDaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		Cemiplimab	Ofatumumab	
DaratumumabTrastuzumabDarvalumabVinblastineEmapalumabVincristine		2-Chlorodeoxyadenosine	Ramucirumab	
DarvalumabVinblastineEmapalumabVincristine		Cladribine	Rituximab	
Emapalumab Vincristine		Daratumumab	Trastuzumab	
Emapalumab Vincristine		Darvalumab	Vinblastine	
		Fludarabine	Vinorelbine	
Iplimumab				

*When combined with cyclophosphamide, these agents are designated as having high emetogenic potential. †Patients treated with carboplatin \geq 4 AUC should be treated with an NK₁ receptor antagonist, and 5-HT₃ receptor antagonist, and dexamethasone.

COVERAGE GUIDELINES

The plan may authorize coverage of a non-preferred anti-emetic medication for Members when **ALL** the following criteria are met:

Anzemet (dolasetron) tablet

1. The member is being treated with chemotherapy that has moderate or high emetogenic potential

AND

2. The member has had an inadequate response, adverse reaction, or contraindication to a trial with generic ondansetron and generic granisetron

Aprepitant oral solution (Emend)

1. The member is being treated with chemotherapy that has moderate or high emetogenic potential, as defined by American Society of Clinical Oncology (ASCO)

AND

2. The member is unable to administer aprepitant capsules due to swallowing difficulties **OR** the member is 6 months through 11 years of age

Doxylamine/pyridoxine (Diclegis)

1. The Member is diagnosed with nausea and vomiting associated with pregnancy

AND

2. The Member had an inadequate response to concurrent therapy with over-the counter doxylamine and pyridoxine, or the provider indicates clinical inappropriateness of treatment with the concurrent use of over-the counter doxylamine and pyridoxine

Doxylamine/pyridoxine ER (Bonjesta)

1. The Member is diagnosed with nausea and vomiting associated with pregnancy

AND

2. The Member had an inadequate response to concurrent therapy with over-the counter doxylamine and pyridoxine, or the provider indicates clinical inappropriateness of treatment with the concurrent use of over-the counter doxylamine and pyridoxine

AND

3. The Member has had an inadequate response to Diclegis (doxylamine/pyridoxine)

Dronabinol oral solution (Syndros)

- 1. The Member has one of the following diagnoses:
 - a. Anorexia associated with weight loss in patients with AIDS
 - b. Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

AND

2. Provider indicates a clinical rationale why the Member is unable to administer generic dronabinol oral capsules (e.g., swallowing difficulties)

Granisetron transdermal (Sancuso)

1. The member has had an inadequate response or intolerance to generic ondansetron and generic granisetron

OR

The member is unable to administer or had an inadequate response to generic ondansetron oral dispersible tablet (ODT)

Netupitant/palonosetron (Akynzeo) capsule, Rolapitant (Varubi) tablet

1. The member is being treated with chemotherapy that had moderate or high emetogenic potential, as defined by American Society of Clinical Oncology (ASCO)

AND

2. The member has had an inadequate response, intolerance, or contraindication to a trial of aprepitant oral capsule in combination with a serotonin antagonist (e.g., ondansetron, granisetron) and dexamethasone

LIMITATIONS

- 1. Akynzeo (netupitant/palonosetron) capsule is limited to one capsule per prescription.
- 2. Anzemet (dolasetron) 50 mg tablet is limited to 5 tablets per fill.
- 3. Aprepitant capsule is limited to 6 capsules per fill.
- 4. Emend (aprepitant) oral solution is limited to 3 units per 7 days.
- 5. Sancuso (granisetron) is limited to one transdermal patch per 7 days, not to exceed 4 patches per 28 days.
- 6. Varubi (rolapitant) tablet is limited to 6 tablets every 30 days and 2 tablets per fill.
- 7. Approval duration of Diclegis (doxylamine/pyridoxine) and Bonjesta is nine months.

CODES

None

REFERENCES

- 1. Akynzeo (netupitant and palonsetron) [prescribing information]. Iselin, NJ: Helsinn Therapeutics; Decembersanc 2023.
- 2. Anzemet (dolasetron) [prescribing information]. Parisppany, NJ: Validus Pharmaceuticals LLC; December 2023.
- 3. Aprepitant capsule [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc.; September 2022.
- 4. Bonjesta (doxyamine/pyridoxine ER) [prescribing information]. Princeton, NJ: Duchesnay USA, Inc; July 2023.
- 5. Diclegis (doxylamine/pyridoxine) [package insert]. Princeton, NJ: Duchesnay USA, Inc.; June 2023.
- 6. Emend (aprepitant) [package insert]. Rahway, NJ: Merch Sharp & Dohme LLC; July 2024.
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782-2797.
- 8. Koren G, Clark S, Hankins GDV, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. *Am J Obstet Gynecol*. 2010;203(6):571.e1-7.
- 9. Sancuso (granisetron) [prescribing information]. Bedminster, NJ: Kywona Kirin, Inc; April 2020..
- 10. Syndros (dronabinol) [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc; September 2022.
- 11. Varubi (rolapitant) [prescribing information]. Lake Forest, IL: TerSera Therapeutics LLC; August 2020.

APPROVAL HISTORY

October 11, 2022: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

- 1. November 14, 2023: Effective December 1, 2023, removed Anzemet 100 mg and nabilone from the MNG due to product discontinuation. Updated previous trial language throughout the MNG. Updated Sancuso criteria to remove required length of chemotherapy treatment. Updated fax number for Pharmacy Utilization Management.
- 2. November 12, 2024: No changes

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

Provider Services